Vaxcyte appoints Jacks Lee to Board of Directors, effective Nov 27, 2023

Vaxcyte, Inc.

Jacks Lee appointed as Class II director, term expires at 2025 annual meeting.
Lee appointed to Audit Committee; Board determined independent under Nasdaq rules.
Initial grant of 30,000 stock options, vesting 1/3 at one year and monthly over 36 months.
Annual grants: option for 15,000 shares and 2,500 RSUs, with accelerated vesting on change of control.
Annual cash retainers: $40,000 for Board service, plus $10,000 for Audit Committee.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Jacks Lee

Class II Director

PCVX · Vaxcyte, Inc.

Effective: 2023-11-27
Filed: November 28, 2023, 6:59 PM ET

appointed Jacks Lee to the Board as a Class II director

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Jacks Lee was appointed as Class II Director at Vaxcyte, Inc..

Action: appointed
Role: Class II Director

Exact text from the filing

appointed Jacks Lee to the Board as a Class II director

View on SEC.gov

Vaxcyte, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-23-283769

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.